Abstract: Noninvasive imaging assessment of tumor cell proliferation could be helpful in the evaluation of tumor growth potential, the degree of malignancy, and could provide an early assessment of treatment response prior to changes in tumor size determined by computed tomography (CT), magnetic resonance imaging (MRI), Positron emission tomography (PET), Single-Photon emission computed tomography (SPECT) or ultrasonography, respectfully. Understanding of tumor proliferative activity, in turn, could aid in the selection of optimal therapy by estimating patient prognosis and selecting the proper management. PET/CT imaging of 18 F-fluoro-2-deoxy-glucose (FDG) is recognized as a technology for diagnosing the presence and extent of several cancer types. Recently, radiolabeled glucosamine analogues were introduced as a promising SPECT agent to complement FDG imaging to increase specificity and improve the accuracy of lesion size in oncology applications. Radiolabeled glucosamine analogues were developed to localize in the nuclear components of cells primarily via the hexosamine biosynthetic pathway whereas glucose localizes in the cytoplasm of cells through the glycolytic/TCA pathway. This paper reviews novel kit-based radiolabeled glucosamine analogues for metabolic imaging of tumor lesions. The novel radiolabeled glucosamine analogues may increase the specificity in oncology applications and can influence patient diagnosis, planning and monitoring of cancer treatment.
IMPORTANCE OF NUCLEAR MOLECULAR IMAGING IN ONCOLOGY
Drug discovery is accelerating due to mapping of molecular targets and the rapid synthesis of high-throughput in vitro testing of compounds in their early stage of the drug development process. The development of radiolabeled biochemical compounds, understanding molecular pathways and imaging devices to detect the radioactivity by external imaging has expanded the use of nuclear molecular imaging studies in drug development. Nuclear molecular imaging modalities (Positron Emission Tomography, PET; Single Photon Emission Computed Tomography, SPECT) map the location and concentration of radionuclide-labeled compounds [1] [2] [3] . At present, PET and SPECT gamma cameras are hybrid with computed tomography (CT) to enhance their sensitivity to quantify drug properties in vivo in real time dynamic events. PET/CT and SPECT/CT are better than PET and SPECT alone because multiple slices by CT and serial images by PET and SPECT provide better delineation in tumor volumes. In addition, combining the anatomical and morphological location from CT, such as SPECT/CT and PET/CT provides the capability to accurately evaluate post-therapy anatomic alteration. PET/CT and SPECT/CT agents show high specific activities because they are made through a nuclear transformation and use carrier free forms of isotopes. Moreover, PET/CT and SPECT/CT chelator-based agents do not produce detectable pharmacologic effects but provide important information concerning the characterization of varieties diseases, such as vascular angiogenesis [4] [5] [6] , hypoxia [7] [8] [9] , apoptosis [10] [11] , cellular signaling and transcriptional activity [12] [13] [14] . PET/CT and SPECT/CT may assist in the determination of optimal therapeutic dosing, differential diagnosis between inflammation/infection and recurrence, sensitive or resistant to treatment response, grading of tumors, and the prediction of treatment response by selecting patient who may or may not respond to therapy. On the other hand, CT, magnetic resonance imaging (MRI), and ultrasound are prognostic tools because they do not provide cellular target information, thus, assessment of the effectiveness of cancer therapy is not optimal. 
KITS CONTAINING RADIONUCLIDES AND CHELATION IN ONCOLOGY
Radionuclide generator systems that can be produced in a well controlled facility and have a long history of successful clinical application would provide an easy and accessible radioisotope for clinical radiopharmaceutical agents. A generator uses a parentdaughter nuclide pair wherein a relatively long-lived parent isotope decays to a short-lived daughter isotope which is used for imaging. The parent isotope, which is produced at a cyclotron facility, is shipped to clinical sites and from which the daughter isotope is eluted on site for clinical use. Nuclear Pharmacies at hospital frequently used generator-produced isotopes are shown in Table 1 [15] . It implies that with the spatial resolution at 5 to 7 mm of current clinical scanners, the imaging quality using 68 Ga-tracers can be as good as that of 18 F-agents. The results of this theoretical analysis are substantiated clinically by the images with satisfactory qualities presented in a recent study in which patients with carcinoid tumors were imaged with 68 Ga-DOTATOC (somatostatin receptor tracers) by PET [16] . 99m Tc (drug product) could be easily achieved in high yield. This unique chelation technology has commercial interests and is an alternative to complex radiochemistry production. The longer halflife of 99m Tc provides an opportunity for serial imaging studies that helps in differential diagnosis and responsiveness evaluation. The ineffective treatment could be stopped in early phases and possible switching to more effective treatments which may be beneficial to patients early on in the course of their treatment.
However, among the kits for theranostic radionuclides, 188 Re has good characteristics because of its ß energy (2.1 MeV), its short physical half-life (16.9 hr) and its 155keV -ray emission for dosimetric and imaging purposes. The short physical half-life of 188 Re allows for higher doses compared with long-lived radionuclides. Furthermore, the short half-life reduces the problems of radioactive waste handling and storage. In particular, 188 Re is available from in-house generator system similar to 99m Tc generator. 188 Re can be obtained from a 188 W/ 188 Re generator, which makes it very convenient for clinical use. The generatorproduced radionuclide, 188 Re, is carrier free and might offer higher specific activity (37,000-74,000 MBq/mg). 188 Re has been applied for a variety of therapeutic applications including radioimmunotherapy [17, 18] , and use 188 Re-microspheres and colloids for potential treatment of rheumatoid arthritis of the synovial joints [19, 20] and hepatoma [21, 22] . An initial feasibility study with 188 Re-hydroxyethylidene diphosphonate ( 188 Re-HEDP) using different 188 Re sources demonstrated that application of 188 Re-HEDP is safe and successful in pain relief palliation [23] . In addition, dose escalation studied with 188 Re-HEDP in prostate cancer patients showed that 3.3 GBq (90 mCi) dose is the maximum tolerated [24] .
Moreover, in order to develop the technology for "personalized medicine for right diagnosis and for early and right medication", a chelator-based technology is of essence. Because chelators could coordinate radiometals and metals for image-guided target assessment and patient selection, the approach maybe the cornerstone for theranostic applications. Several chelators have been reported such as N 4 (e.g. Cyclam-14, DOTA), N 3 S (e.g. MAG-3), N 2 S 2 (e.g. ECD), NS 3, S 4 (e.g. sulfur colloid), diethylenetriamine pentaacetate (DTPA), O 2 S 2 (e.g. DMSA), and hydrazinenicotinamide (HYNIC) [25] [26] [27] [28] [29] . Among these chelators for example, DTPA has been shown to have a faster wash out and forms less stable complexes with 99m Tc. 99m Tc-HYNIC has been shown to be useful in imaging, but labeling HYNIC with 99m Tc requires two chemicals, triphenylphosphine and tricine, which are inconvenient for the kit preparation. As for as the most stable formation, may be the nitrogen and sulfur combination which has been shown to be a very stable chelator for 99m Tc-bisaminoethanethiol tetradentate ligands, also called diaminodithiol compounds. These are also known to form very stable Tc(V)Ocomplexes on the basis of efficient binding of the oxotechnetium group to two thiosulfur and two amine nitrogen atoms. Therefore, L,L-ethylenedicysteine (EC) is the most successful example of N 2 S 2 chelates [30] [31] [32] [33] of this combination. In addition, EC can be labeled with radiometals efficiently with high radiochemical purity and the preparation remains stable for several hours [34] [35] [36] . The strong complexing property of such N 2 S 2 -tetraligand systems is also used for labeling of proteins and peptides with radiometals for theranostic applications after conjugation to a bisaminothiol derivative [37] [38] [39] . In this report, a series of EC, DTPA, and MAG-3 chelators in the imaging of hexosamine biosynthetic pathway in oncology are reviewed.
METABOLIC IMAGING OF HEXOSAMINE BIOSYNT-HETIC PATHWAY IN ONCOLOGY
Molecular imaging in oncology has been focused on identification of specific markers and the application of these markers for evaluation of patient response to radiation therapy, chemotherapy or chemo/radiotherapy. The radiotracer could noninvasively assess diseases treatment endpoints which used to rely almost exclusively on biopsies, histopathological assays and now biomarkers. For example, one radiotracer which is considered a molecular imaging marker is 18 F-fluoro-2-deoxy-glucose (FDG), a gold standard for PET. This molecular imaging marker is complementary to the CT and MRI, which allows detection of unsuspected distant metastases disease. Though FDG-PET is concordant with the findings of CT and MRI in diagnosing various tumors, FDG also has its drawbacks. FDG utilizes two main glucose transporters and hexokinase phosphorylated processes but becomes trapped and gets cycled for tumor imaging [40] [41] [42] . This makes FDG exhibits poor differentiation between inflammation/ infection and tumor recurrence due to its high uptake in granulocytes, macrophages and in tissues which may take up high levels of glucose [43] . One example, FDG has poor contrast in brain tumors due to the high uptake of glucose in normal brain tissue [44] . Because of patterns like brain and white cells, FDG does not provide the selection of patients for therapeutic response. Therefore, it is amenable to develop an alternative radiotracer for better differential diagnosis and responsiveness in cancers.
Metabolic imaging glucose and glucosamine agents which enters into the cell via hexosamine biosynthetic pathway and its regulatory products of glucosamine-6-phosphate becomes that involves insulin activation, downstream signaling and translocation, which upregulate mRNA expression and tumor growth [45] [46] [47] [48] [49] [50] [51] [52] may be of great interest in monitoring post therapy changes in patients treatment. The hexosamine biosynthetic pathway is shown in Fig.  (1) . In the hexosamine biosynthetic pathway, glutamine:fructose-6-phosphate amidotransferase (GFAT) uses the amide group of glutamine to convert fructose 6-phosphate to glucosamine 6-phosphate, thus formation of hexosamine products requires a supply of both glucose and glutamine [45] [46] . Metabolic imaging glucosamine and N-acetylglucosamine interaction with uridine diphosphate (UDP) to UDP-N-acetylglucosamine to monitor its interaction with other cell factors is very important in nuclear molecular imaging. For example, O-linked N-acetylglucosamine transferase (OGT) catalyzes UDP-GlcNAc to a single GlcNAc in glycosylation to serine or threonine residues of transcription factors (i.e. NF-kB) for nuclear trafficking and transactivation. OGT protein may be a sensor to activate UDP-N-acetylglucosamine to interact with protein to form unique glycoprotein, which involves nuclear and cytosolic protein interactions. Being able to image and monitor this dynamic glycosylation of serine or threonine residues on nuclear and cytosolic protiens by OGT that is abundant in all multicellular eukaryotes may be the most important molcular imaging function to perform in nuclear medicine. In fact, having to correlate nuclear molecular imaging techniques with the activities of OGT which is a part of post-translational modification that appears to modify a large number of nucleocytoplasmic proteins changes is critcal in staging patients with cancer. This factor known as OGT, performs activities which exquisitely responsive to intracellular UDP-N-acetylglucosamine and UDP concentrations, which are in turn highly sensitive to glucose concentrations and other stimuli that may have an hugh impact on pateints that may be treated with chemodrugs. Since this phenomenom is so dynamic and is often in response to different stimuli, for example stress because so many cancer pateints are stressed, (stress, heat) and to monitor the true changes of the nucleus and its ability to become internalized by the cell nucleus and tract its interaction may provide a great value to nuclear medicince as a whole [47] [48] [49] [50] . Therefore, this should be viewed as true molecular medicine which imaging can be intergrated for better understanding how the cell nucleus, can interact with ubiquitous transcription factors, such as Sp1 which can be extensively modified by OGT that's been tagged. Moreover, as one transcription factor like Sp1 becomes hyperglycosylated in response to hyperglycemia or elevated glucosamine [51] [52] , this process can be monitor and evaluated by nuclear imaging techniques.
RADIOLABELED GLUCOSAMINE ANALOGUES AS ALTERNATIVE CHELATOR-BASED RADIOTRACERS BEYOND FDG
The key to glucosamine analogue uniqueness as a target specific molecular compound is that it uses a chelator, radiolabeled with 99m Tc which is commonly used in nuclear medicine and mimics the naive glucosamine in man. Three radiolabeled glucosamine analogues are reviewed.
They are MAG-3-glucosamine [53] , DTPA-glucosamine [54] [55] [56] [57] [58] , and ECglucosamine (EC-G) [59] [60] [61] . The structures are shown in Fig. (2) . For example, EC-G is not radioactive, and thus, is a pharmaceutical compound. This compound only becomes a radiopharmaceutical when the 99m Tc is added and reduced with a reducing agent. However, FDG is manufactured by a cyclotron, radiolabeled with 18 F and does not mimic navie glucose. In essence, when FDG is manufactured in a cyclotron, the radioisotope, fluorine-18 is an integral part of the compound. In other words, FDG is radioactive the moment it is manufactured. Although, EC-G and FDG bear certain common features, it's the dissimilarities that are the most important features to point out. For example, both compounds use sugar analogues for targeting when the compounds are taken up by the tumor cells that how they are utilized by the cell is what makes the difference so dramatic. FDG gets trapped in the cell's cytoplasm while EC-G is translocated into the cell's nuclei where the DNA resides. This explains, in part, why FDG gets taken up in inflamed or infected tissue and EC-G does not. Another feature is that because of FDG charge, it crosses the blood-brain-barrier and saturates a normal brain. However, EC-G does not cross a normal blood-brain-barrier unless there is a break down in the brain barrier due to an insult to the brain. 99m Tc-EC-G has been shown to exhibit characteristics similar to FDG in terms of the glucose membrane transport process which involves the glycolytic and hexosamine pathways several past studies. Lastly, the mechanism of action and the negative charge of FDG are the primary reasons why FDG cannot be a platform for a therapeutic compound. Conversely, EC-G is an excellent platform for a therapeutic compound. However, several other chelators must be mention in this class but doesn't have the full capable of radiolabeled EC-G.
The difference in MAG-3-glucosamine, DTPA-glucosamine, and EC-G structures is that only EC-G has two glucosamine moieties in the molecule and others do not. Synthesis of DTPA-DG was achieved by reacting glucosamine with DTPA-dianhydride in the presence of triethylamine, followed by sephadex purification [54] . The chemical modification may change the characterics of a glycoprotein is transported in the cell. MAG-3 chelator was conjugated at the position 1 of glucosamine, which has similar chemistry that was performed in 1-thioglucose [62] . The authors reported the similar biodistribution pattern in normal mice between MAG-3-glucosmaine and MAG-3-glucose. However, there were neither a tumor model nor human studies to affirm the effectivenss of MAG-3-glucosmaine. Although, DTPA-glucosamine was labeled with 99m Tc and 188 Re, respectively [54] [55] [56] [57] [58] , it exhibited a faster clearance in animal studies, thus, the tumor registration was low. Again, it has been discovered that radiolabeled EC-G behaves, in certain respects, quite differently than radiolabeded FDG. For instance, a hexokinase assay is based upon the reduction of NAD + through a coupled reaction with glucose-6-phosphate dehydrogenase to produce NADH. Both EC-G and FDG demonstrate that they can be phosphorylated and sequestered in glucose-energydependent cells similarly to glucose itself. However, the magnitude of EC-G to produce NADH is less than FDG suggesting that either the rate limiting step of phosphorylation in EC-G is slower than FDG or EC-G is more involved in downstream signature event than FDG [59] . Subsequently, our cell cycle analysis revealed that 99m Tc-EC-G was able to transport across the nucleus membrane and involved in proliferation activity in all phases of cell cycles [60] . Moreover, the radiolabeded uptake studies of FDG, glucose and glucosamine correlated well with the thymidine incorporation assay studies with unlabeled EC-G and glucose suggesting both EC-G and glucose were involved in the proliferation/growth activity of cells, whereas FDG was not [59, 60, 63] .
The lack of FDG involvement in DNA proliferation is attributable to the presence of the fluorine atom at position 2 of the molecule, which prevents its recognition by UDP and consequently its utilization in cell proliferation and growth. Two sets of glucose transporters are involved in this process which are transporters 1 and 3, and transporters 2 and 4 [47] , respectfully. The clinical Phase I and II trials revealed that 99m Tc-EC-G was safe and had favorable radiation dosimetry, and was able to differentiate tumor from infammation in lung cancer patients [61] , respectfully. Consequently, 99m Tc-EC-G offer the potential to be the standard SPECT imaging agent for screening, diagnosing and staging for all cancer types [61] .
Cancer cells upregulate glycolysis, increasing glucose uptake to meet energy needs. A small fraction of a cell's glucose enters the hexosamine biosynthetic pathway which regulates levels of GFAT and OGT. Elevated expression of OGT, which is the enzyme catalyzing the addition of O-GlcNAc to proteins, enhances posttranslational modification of diverse nuclear and cytosolic proteins. Reduction of O-GlcNAcation through RNA interference of OGT in cancer cells may lead to inhibition of tumor growth both in vitro and in vivo and is associated with decreased cell-cycle progression. These findings identify O-GlcNAc as a novel mechanism through which alterations in glucose metabolism regulate cancer growth and invasion and suggest that OGT may represent novel therapeutic targets for cancers. Thus, the hexoamine biosynthetic pathway-based radiotracer may provide more accurate information on molecular image-guided therapy.
In summary, the cold kit precursor is considered as drug substance thus it is easier in chemistry, manufacturing and control (CMC) standardization. Kit-based radiotracers provide an opportunity for better differentiation between infection/ inflammation and tumor recurrence than FDG in human. The kitbased radiotracers may discontinue ineffective treatment in an earlier phase and switch to a more efficient treatment that would be beneficial to patients early on in the course of treatment.
